Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories consolidated Net Sales ($M) ($M)
Postgres DB financial_values + Form 10-K/10-Q XBRL
Latest, Q2 2026
12,593
Period ended Jun 30, 2026
Change on a year earlier
+13.0%
11,142 in Q2 2025
History
74 quarters
Since Q1 2008
Sources
51
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated Net Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 12,593 | +13.0% | Form 10-Q (filed 2026-07-28) ↗ |
| Q1 2026 | Mar 31, 2026 | 11,164 | +7.8% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 11,459 | +4.4% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 11,369 | +6.9% | Form 10-Q (filed 2025-10-29) ↗ |
| Q2 2025 | Jun 30, 2025 | 11,142 | +7.4% | Form 10-Q (filed 2025-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 10,358 | +4.0% | Form 10-Q (filed 2025-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 10,974 | +7.2% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2024 | Sep 30, 2024 | 10,635 | +4.9% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 10,377 | +4.0% | Form 10-Q (filed 2024-07-31) ↗ |
| Q1 2024 | Mar 31, 2024 | 9,964 | +2.2% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 10,241 | +1.5% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2023 | Sep 30, 2023 | 10,143 | -2.6% | Form 10-Q (filed 2023-11-01) ↗ |
| Q2 2023 | Jun 30, 2023 | 9,978 | -11.4% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 9,747 | -18.1% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 10,091 | -12.0% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2022 | Sep 30, 2022 | 10,410 | -4.7% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2022 | Jun 30, 2022 | 11,257 | +10.1% | Form 10-Q (filed 2022-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 11,895 | +13.8% | Form 10-Q (filed 2022-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 11,468 | +7.2% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 10,928 | +23.4% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 10,223 | +39.5% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 10,456 | +35.3% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 10,701 | +28.7% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 8,853 | +9.6% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 7,328 | -8.2% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 7,726 | +2.5% | Form 10-Q (filed 2020-04-29) ↗ |
| Q4 2019 | Dec 31, 2019 | 8,314 | +7.1% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 8,076 | +5.5% | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 7,979 | +2.7% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 7,535 | +2.0% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 7,765 | +2.3% | Form 10-K (filed 2019-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 7,656 | +12.1% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 7,767 | +17.0% | Form 10-Q (filed 2018-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | 7,390 | +16.7% | Form 10-Q (filed 2018-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 7,589 | +42.3% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2017 | Sep 30, 2017 | 6,829 | +28.8% | Form 10-Q (filed 2017-11-02) ↗ |
| Q2 2017 | Jun 30, 2017 | 6,637 | +24.5% | Form 10-Q (filed 2017-08-02) ↗ |
| Q1 2017 | Mar 31, 2017 | 6,335 | +29.7% | Form 10-Q (filed 2017-05-03) ↗ |
| Q4 2016 | Dec 31, 2016 | 5,333 | +2.8% | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2016 | Sep 30, 2016 | 5,302 | +3.0% | Form 10-Q (filed 2016-11-03) ↗ |
| Q2 2016 | Jun 30, 2016 | 5,333 | +3.2% | Form 10-Q (filed 2016-08-03) ↗ |
| Q1 2016 | Mar 31, 2016 | 4,885 | -0.2% | Form 10-Q (filed 2016-05-04) ↗ |
| Q4 2015 | Dec 31, 2015 | 5,188 | -3.1% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 5,150 | +1.4% | Form 10-Q (filed 2015-11-05) ↗ |
| Q2 2015 | Jun 30, 2015 | 5,170 | +2.2% | Form 10-Q (filed 2015-08-04) ↗ |
| Q1 2015 | Mar 31, 2015 | 4,897 | +3.0% | Form 10-Q (filed 2015-05-06) ↗ |
| Q4 2014 | Dec 31, 2014 | 5,356 | +5.6% | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2014 | Sep 30, 2014 | 5,079 | +5.7% | Form 10-K (filed 2015-02-27) ↗ |
| Q2 2014 | Jun 30, 2014 | 5,057 | +2.5% | Form 10-K (filed 2015-02-27) ↗ |
| Q1 2014 | Mar 31, 2014 | 4,755 | -1.9% | Form 10-K (filed 2015-02-27) ↗ |
| Q4 2013 | Dec 31, 2013 | 5,072 | -9.9% | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2013 | Sep 30, 2013 | 4,805 | -8.7% | Form 10-K (filed 2015-02-27) ↗ |
| Q2 2013 | Jun 30, 2013 | 4,933 | -7.2% | Form 10-K (filed 2015-02-27) ↗ |
| Q1 2013 | Mar 31, 2013 | 4,847 | -8.3% | Form 10-K (filed 2015-02-27) ↗ |
| Q4 2012 | Dec 31, 2012 | 5,632 | -45.7% | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2012 | Sep 30, 2012 | 5,265 | -46.4% | Form 10-K (filed 2014-02-21) ↗ |
| Q2 2012 | Jun 30, 2012 | 5,313 | -44.7% | Form 10-K (filed 2014-02-21) ↗ |
| Q1 2012 | Mar 31, 2012 | 5,284 | -41.6% | Form 10-K (filed 2014-02-21) ↗ |
| Q4 2011 | Dec 31, 2011 | 10,377 | +4.1% | Form 10-K (filed 2012-02-21) ↗ |
| Q3 2011 | Sep 30, 2011 | 9,817 | +13.2% | Form 10-K (filed 2013-02-15) ↗ |
| Q2 2011 | Jun 30, 2011 | 9,616 | +9.0% | Form 10-K (filed 2013-02-15) ↗ |
| Q1 2011 | Mar 31, 2011 | 9,041 | +17.4% | Form 10-K (filed 2013-02-15) ↗ |
| Q4 2010 | Dec 31, 2010 | 9,968 | +13.4% | Form 10-K (filed 2011-02-18) ↗ |
| Q3 2010 | Sep 30, 2010 | 8,674 | +11.8% | Form 10-K (filed 2012-02-21) ↗ |
| Q2 2010 | Jun 30, 2010 | 8,826 | +17.8% | Form 10-K (filed 2012-02-21) ↗ |
| Q1 2010 | Mar 31, 2010 | 7,698 | +14.6% | Form 10-K (filed 2012-02-21) ↗ |
| Q4 2009 | Dec 31, 2009 | 8,790 | +10.6% | Form 10-K (filed 2011-02-18) ↗ |
| Q3 2009 | Sep 30, 2009 | 7,761 | +3.5% | Form 10-K (filed 2011-02-18) ↗ |
| Q2 2009 | Jun 30, 2009 | 7,495 | +2.5% | Form 10-K (filed 2011-02-18) ↗ |
| Q1 2009 | Mar 31, 2009 | 6,718 | -0.7% | Form 10-K (filed 2011-02-18) ↗ |
| Q4 2008 | Dec 31, 2008 | 7,950 | – | Form 10-K (filed 2011-02-18) ↗ |
| Q3 2008 | Sep 30, 2008 | 7,498 | – | Form 10-K (filed 2011-02-18) ↗ |
| Q2 2008 | Jun 30, 2008 | 7,314 | – | Form 10-K (filed 2011-02-18) ↗ |
| Q1 2008 | Mar 31, 2008 | 6,766 | – | Form 10-K (filed 2011-02-18) ↗ |
Breakdown
What makes up consolidated net sales ($m)
- Cost of Products Sold ($M)5,325 · Q2 2026
- GAAP Gross Margin ($M)6,544 · Q3 2026
- Research & Development Expense ($M)892 · Q2 2026
- Selling, General & Administrative Expense ($M)4,025 · Q2 2026
- Operating Earnings ($M)1,693 · Q2 2026
- Interest Expense ($M)351 · Q2 2026
- Earnings Before Taxes ($M)1,524 · Q2 2026
- Taxes on Earnings ($M)596 · Q2 2026
- Net Earnings ($M)928 · Q2 2026
- Diluted Earnings Per Common Share ($/share)0.53 · Q2 2026
- Weighted-Average Diluted Shares Outstanding (Millions)1,743 · Q2 2026
Cite this data
StockData. (2026). Abbott Laboratories Consolidated Net Sales ($M) ($M), quarterly Q1 2008–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/db-is-rev
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.